Abstract
Prostate cancer is a significant health problem for men in the United States. While useful treatment modalities are available, their therapeutic efficacies are limited and severe side effects remain a concern. Alternatively, immunotherapy represents one of the most valuable treatments by inducing immune response targeting tumor cells. Sipuleucel-T is the only FDA approved immunotherapeutic agent for the treatment of patients with metastatic castration-resistant prostate cancer. Overall survival benefit with sipuleucel-T is modest, and the research field of cancer immunotherapy is continuously expanding. Numerous methods designed to induce tumor-specific immunity are at various developmental stages in clinical and preclinical studies. Among such modalities, the use of adenovirus vector (Ad) as an immunotherapy agent to deliver tumor-associated antigens is an attractive and versatile vector system. In this review, we describe the potential use of Ad-vector for prostate cancer immunotherapy.
Keywords: Prostate cancer vaccine, adenovirus vaccine, immunotherapy
Current Cancer Therapy Reviews
Title:Adenovirus-based Immunotherapy for Prostate Cancer
Volume: 8 Issue: 4
Author(s): Seema Dubey, Peter VanVeldhuizen and Dev Karan
Affiliation:
Keywords: Prostate cancer vaccine, adenovirus vaccine, immunotherapy
Abstract: Prostate cancer is a significant health problem for men in the United States. While useful treatment modalities are available, their therapeutic efficacies are limited and severe side effects remain a concern. Alternatively, immunotherapy represents one of the most valuable treatments by inducing immune response targeting tumor cells. Sipuleucel-T is the only FDA approved immunotherapeutic agent for the treatment of patients with metastatic castration-resistant prostate cancer. Overall survival benefit with sipuleucel-T is modest, and the research field of cancer immunotherapy is continuously expanding. Numerous methods designed to induce tumor-specific immunity are at various developmental stages in clinical and preclinical studies. Among such modalities, the use of adenovirus vector (Ad) as an immunotherapy agent to deliver tumor-associated antigens is an attractive and versatile vector system. In this review, we describe the potential use of Ad-vector for prostate cancer immunotherapy.
Export Options
About this article
Cite this article as:
Dubey Seema, VanVeldhuizen Peter and Karan Dev, Adenovirus-based Immunotherapy for Prostate Cancer, Current Cancer Therapy Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/1573394711208040264
DOI https://dx.doi.org/10.2174/1573394711208040264 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Meet the Editorial Board
Current Drug Targets The Role of Neuropeptide Processing Enzymes in Endocrine (Prostate) Cancer: EC 3.4.24.15 (EP24.15)
Protein & Peptide Letters The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry Ion Transporters in Brain Tumors
Current Medicinal Chemistry Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology
Current Neuropharmacology Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Protein & Peptide Letters The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry New Targets, New Agents, and the Evolving Phenomena of Drug Resistance in Cancer
Current Cancer Therapy Reviews Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) 3,4,5-Trisubstituted-1,2,4-triazole Derivatives as Antiproliferative Agents: Synthesis, In vitro Evaluation and Molecular Modelling
Letters in Drug Design & Discovery